KDC-MN-090 – Kodiac biolabs

Plain-language summaryIntrigue 70 / 100

Follistatin-315 is the 315-amino-acid isoform of follistatin, which differs from FST-344 by tissue distribution and binding partners. Same general myostatin-blocking function. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

37/100

PK-improved follistatin isoform with real bench utility but thin isoform-specific clinical evidence

Look, follistatin biology is not new territory. The basic story, that sequestering myostatin and activin A produces meaningful muscle hypertrophy and anti-fibrotic effects, has been sitting in the literature since the landmark Lee and McPherron myostatin-knockout mouse work in the late 1990s. What FST-315 brings to the table isnt a new mechanism, it’s a pharmacokinetic refinement that actually matters for research design.

Here’s the thing about follistatin 344: it’s almost entirely tissue-bound. The C-terminal acidic tail drives strong heparan sulfate proteoglycan interactions at the cell surface, which means systemic delivery of FST-344 produces a compound that largely parks itself in local tissue rather than circulating. FST-315, produced by alternative splicing that removes that acidic region, has dramatically reduced heparin affinity and a correspondingly longer plasma half-life. For any research program trying to study systemic myostatin inhibition, this isnt a cosmetic difference. It changes what you can actually measure and when.

We think the mechanistic case is solid. Dual neutralization of both GDF-8 and activin A gives FST-315 a broader profile than single-target anti-myostatin antibodies like trevogrumab, and the activin A arm is increasingly interesting given the literature on activin signaling in cachexia, fibrosis, and bone biology. Bimagrumab, which targets ActRIIA/B (the receptor side of the same pathway), has real clinical traction in metabolic disease models, which at least validates the axis. FST-315 isnt bimagrumab, but it works upstream and hits both ligands rather than the receptor.

What we dont like: there’s no formal clinical development record for FST-315 as a distinct entity. Most of the relevant pharmacokinetic characterization comes from comparative isoform studies, not dedicated FST-315 programs. Human translational signal is essentially borrowed from follistatin biology broadly, and that borrowing is imperfect. The compound is sold as a research peptide with all the sourcing variability that implies.

As a bench tool for investigators studying myostatin/activin signaling in muscle or fibrotic contexts, FST-315 has genuine utility over FST-344 for systemic dosing designs. Thats not nothing. But the dedicated literature is thin, replication outside of foundational isoform characterization studies is limited, and the compound is sitting in a well-understood mechanistic class with more clinically advanced alternatives already in development. Honest assessment: interesting tool, clear rationale for preferring it over FST-344 in certain designs, but not a frontier compound by current standards.

Novelty: 38
Mechanism promise: 45
In-category differentiation: 42
Evidence quality: 28
Translational signal: 22
Research bench value: 48

Rationale FST-315 sits in an active and well-grounded biological space (myostatin/activin A antagonism) but its isoform-specific literature is sparse; the differentiation story is real and mechanistically coherent (reduced heparin binding, longer half-life) but the compound has no independent clinical development record, keeping evidence and translational scores low and dragging the overall into the mid-30s.

Myostatin antagonist / follistatin isoform

A 315-residue isoform of follistatin with reduced heparin binding and longer plasma half-life than follistatin 344.

Abstract

Follistatin 315 is a 315-residue isoform of follistatin produced by alternative splicing of the FST gene, lacking the C-terminal acidic region present in follistatin 344. The compound has reduced heparin binding (which improves plasma circulation; follistatin 344 is largely tissue-bound through cell surface heparan sulfate) and a longer plasma half-life. Like follistatin 344, the compound antagonizes myostatin (GDF-8) and activin A. The compound is sold as a research peptide. There is no formal clinical development record. Investigational doses parallel follistatin 344; safety considerations are similar.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-090Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-090

Follistatin 315

Abstract

Read the full monograph